Area of research
Cardiology and Cardiovascular Medicine
Research interest
Research interests include Atrial Fibrillation Management and Outcomes, Cardiac Arrhythmias and Treatments, Cardiac pacing and defibrillation studies, and Cardiac electrophysiology and arrhythmias.
Catheter Ablation Is Associated With a Decrease in Major Adverse Cardiovascular Events and All-Cause Mortality in Patients With Atrial Fibrillation and Obstructive Sleep Apnea.
Pulsed Field Versus Radiofrequency Ablation in Concomitant Pulmonary Vein Isolation and LAA Occlusion: Impact on Peridevice Leak and Procedural Efficiency.
Pulse Pressure and Gastrointestinal Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: A Real-World Analysis From REACHnet (Preprint)
Gastrointestinal Bleeding Risk Associated With Pulse Pressure in Patients With Atrial Fibrillation: A Retrospective Cohort Study (Preprint)
The senescent heart and atrial fibrillation
Three-Year Outcomes of Catheter Ablation in Patients With End-Stage Heart Failure and Atrial Fibrillation
Sex and Treatment Outcomes of Atrial Fibrillation Ablation in End-Stage Heart Failure
Machine Learning-Driven Identification of Distinct Persistent Atrial Fibrillation Phenotypes: A Cluster Analysis of DECAAF II.
Three-Year Outcomes of Catheter Ablation in Patients With End-Stage Heart Failure and Atrial Fibrillation.
Prediction of Stroke Risk in Patients with Atrial Fibrillation: Comorbidities vs Temporal AF Behavior
Application of artificial intelligence to analyze data from randomized controlled trials: An example from DECAAF II
One-year outcomes of pulmonary vein isolation with a novel cryoballoon: Primary results of the FROZEN AF trial.
Comprehensive atrial fibrillation burden and symptom reduction post-ablation: insights from DECAAF II.
Catheter Ablation in Patients With End-Stage Heart Failure and Atrial Fibrillation: Two-Year Follow-Up of the CASTLE-HTx Trial
Effects of Atrial Fibrillation Ablation on Arrhythmia Burden and Ventricular Function in End-Stage Heart Failure: Lessons from CASTLE-HTx
Catheter Ablation in Patients With End-Stage Heart Failure and Atrial Fibrillation: Two-Year Follow-Up of the CASTLE-HTx Trial.
Preventive Catheter Ablation for Ventricular Arrhythmias in Patients with End-Stage Heart Failure Referred for Heart Transplantation Evaluation: Rationale for and Design of the CASTLE-VT Trial
Lesion monitoring parameters as predictors of atrial arrhythmia recurrence after catheter ablation in persistent AF: A DECAAF II sub-analysis.
Body mass index as a determinant of scar formation post-AF ablation: Insights from DECAAF II.
Women Trainees in Electrophysiology and the Effect of Role Models.
Electrocardiography deep learning models to predict high-risk imaging features in patients with hypertrophic cardiomyopathy: Can it change clinical practice?
One-year outcomes of Pulmonary Vein Isolation with a novel cryoballoon: Primary results of the FROZEN AF Trial
Does early detection of atrial fibrillation reduce the risk of thromboembolic events? Rationale and design of the Heartline study
Effect of fibrosis regionality on atrial fibrillation recurrence: insights from DECAAF II.
Identifying the prognostic significance of early arrhythmia recurrence during the blanking period and the optimal blanking period duration: insights from the DECAAF II study.
Twenty-five years of research in cardiac imaging in electrophysiology procedures for atrial and ventricular arrhythmias.
Catheter ablation improved ejection fraction in persistent AF patients: a DECAAF-II sub analysis.
Compliance Challenges in a Longitudinal COVID-19 Cohort Using Wearables for Continuous Monitoring: Observational Study.
Differences in postablation cardiac MRI scar between radiofrequency and cryoballoon ablation: A DECAAF II subanalysis.
Atrial fibrillation ablation as first-line therapy for patients with heart failure with reduced ejection fraction (HFrEF): evaluating the impact on patient survival.